December 3, 2020 Mr. Rich Lakin, MSPH, MPA Immunizations Director Utah Department of Health Bureau of Epidemiology PO Box 142102 Salt Lake City, UT 84114-2102 Dear Director Lakin: As a state plan for the allocation of COVID-19 vaccinations is formulated, BioUtah urges you to include employees of Utah’s life sciences companies among priority recipients of […]
ProLung, now IONIQ Sciences (IONIQ), has been on a roll! Last week, the company announced that they had fully subscribed a $3.3 million private placement. This week, the company unveiled its new name and also announced the initiation of an institutional private equity offering. The new corporate name – IONIQ Sciences – reflects the company’s mission […]
SALT LAKE CITY, JANUARY 15, 2026—SPARC Health, a collaborative effort between Park City Angels (PCA), BioUtah, BioHive, in partnership with Governor’s Office of Economic Opportunity (GOEO), today announced applications are now open for its second cohort program. The announcement celebrates the impressive achievements of the inaugural cohort and the growing momentum of Utah’s healthcare innovation […]
3 Key takeaways Participants gain a rare platform to pitch to a specialized panel of judges who possess the deep industry expertise required to fund and scale complex medical technologies, pharmaceuticals, and digital health solutions. Following in March, after the global JPMorgan Healthcare Conference, participating companies can take the “JPM momentum” and apply it […]
The purchase is expected to expand Haemonetics’ impact in fast-growing markets for structural heart and endovascular procedures. […]
State-of-the-art, multi-modality breast biopsy system slated to be in the market in early 2026 […]
DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc Disease […]
Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions. […]
Fluidx GPX Embolic Device Pivotal Trial Completes Enrollment […]
Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platform. […]
Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing […]
As we look back at 2025, we’re thankful for the progress our team and partners helped drive this year. […]
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) […]